Literature DB >> 30566043

PLN Foundation.

Evangelia G Kranias1, Pieter A Doevendans2,3, Pieter C Glijnis4, Roger J Hajjar5.   

Abstract

Entities:  

Keywords:  foundation; isoproterenol; mutation; patients; phosphate

Mesh：

Substances：

Year:  2018        PMID： 30566043      PMCID： PMC6363126          DOI： 10.1161/CIRCRESAHA.118.314014

Source DB:  PubMed          Journal:  Circ Res        ISSN： 0009-7330            Impact factor:   17.367


× No keyword cloud information.
  15 in total

Review 1.  Discovery of phospholamban. A personal history.

Authors:  A M Katz
Journal:  Ann N Y Acad Sci       Date:  1998-09-16       Impact factor: 5.691

2.  A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy.

Authors:  Kobra Haghighi; Fotis Kolokathis; Anthony O Gramolini; Jason R Waggoner; Luke Pater; Roy A Lynch; Guo-Chang Fan; Dimitris Tsiapras; Rohan R Parekh; Gerald W Dorn; David H MacLennan; Dimitrios Th Kremastinos; Evangelia G Kranias
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-23       Impact factor: 11.205

3.  Structure of the rabbit phospholamban gene, cloning of the human cDNA, and assignment of the gene to human chromosome 6.

Authors:  J Fujii; A Zarain-Herzberg; H F Willard; M Tada; D H MacLennan
Journal:  J Biol Chem       Date:  1991-06-25       Impact factor: 5.157

4.  Phosphorylation of a 22,000-dalton component of the cardiac sarcoplasmic reticulum by adenosine 3':5'-monophosphate-dependent protein kinase.

Authors:  M Tada; M A Kirchberger; A M Katz
Journal:  J Biol Chem       Date:  1975-04-10       Impact factor: 5.157

5.  The role of phospholamban in the regulation of calcium transport by cardiac sarcoplasmic reticulum.

Authors:  B A Davis; I Edes; R C Gupta; E F Young; H W Kim; N A Steenaart; G Szymanska; E G Kranias
Journal:  Mol Cell Biochem       Date:  1990-12-20       Impact factor: 3.396

6.  Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy.

Authors:  Paul A van der Zwaag; Ingrid A W van Rijsingen; Angeliki Asimaki; Jan D H Jongbloed; Dirk J van Veldhuisen; Ans C P Wiesfeld; Moniek G P J Cox; Laura T van Lochem; Rudolf A de Boer; Robert M W Hofstra; Imke Christiaans; Karin Y van Spaendonck-Zwarts; Ronald H Lekanne dit Deprez; Daniel P Judge; Hugh Calkins; Albert J H Suurmeijer; Richard N W Hauer; Jeffrey E Saffitz; Arthur A M Wilde; Maarten P van den Berg; J Peter van Tintelen
Journal:  Eur J Heart Fail       Date:  2012-07-20       Impact factor: 15.534

7.  Mutations in the human phospholamban gene in patients with heart failure.

Authors:  Alessandra Medeiros; Diogo G Biagi; Tiago J P Sobreira; Paulo Sérgio L de Oliveira; Carlos Eduardo Negrão; Alfredo J Mansur; José Eduardo Krieger; Patricia C Brum; Alexandre C Pereira
Journal:  Am Heart J       Date:  2011-11-08       Impact factor: 4.749

8.  Cardiac-specific overexpression of phospholamban alters calcium kinetics and resultant cardiomyocyte mechanics in transgenic mice.

Authors:  V J Kadambi; S Ponniah; J M Harrer; B D Hoit; G W Dorn; R A Walsh; E G Kranias
Journal:  J Clin Invest       Date:  1996-01-15       Impact factor: 14.808

9.  Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human.

Authors:  Kobra Haghighi; Fotis Kolokathis; Luke Pater; Roy A Lynch; Michio Asahi; Anthony O Gramolini; Guo-Chang Fan; Dimitris Tsiapras; Harvey S Hahn; Stamatis Adamopoulos; Stephen B Liggett; Gerald W Dorn; David H MacLennan; Dimitrios T Kremastinos; Evangelia G Kranias
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

Review 10.  Prevalence and cardiac phenotype of patients with a phospholamban mutation.

Authors:  I E Hof; J F van der Heijden; E G Kranias; D Sanoudou; R A de Boer; J P van Tintelen; P A van der Zwaag; P A Doevendans
Journal:  Neth Heart J       Date:  2019-02       Impact factor: 2.380
View more
  4 in total

1.  Aberrant PLN-R14del Protein Interactions Intensify SERCA2a Inhibition, Driving Impaired Ca2+ Handling and Arrhythmogenesis.

Authors:  Elizabeth Vafiadaki; Kobra Haghighi; Demetrios A Arvanitis; Evangelia G Kranias; Despina Sanoudou
Journal:  Int J Mol Sci       Date:  2022-06-22       Impact factor: 6.208

2.  Chronic cardiac structural damage, diastolic and systolic dysfunction following acute myocardial injury due to bromine exposure in rats.

Authors:  Louis J Dell'Italia; Shama Ahmad; Juan Xavier Masjoan Juncos; Shazia Shakil; Wayne E Bradley; Chih-Chang Wei; Iram Zafar; Pamela Powell; Nithya Mariappan; William E Louch; David A Ford; Aftab Ahmad
Journal:  Arch Toxicol       Date:  2020-09-26       Impact factor: 5.153

3.  Behavioral and Neuronal Effects of Inhaled Bromine Gas: Oxidative Brain Stem Damage.

Authors:  Shazia Shakil; Juan Xavier Masjoan Juncos; Nithya Mariappan; Iram Zafar; Apoorva Amudhan; Archita Amudhan; Duha Aishah; Simmone Siddiqui; Shajer Manzoor; Cristina M Santana; Wilson K Rumbeiha; Samina Salim; Aftab Ahmad; Shama Ahmad
Journal:  Int J Mol Sci       Date:  2021-06-12       Impact factor: 5.923

4.  Impaired Right Ventricular Calcium Cycling Is an Early Risk Factor in R14del-Phospholamban Arrhythmias.

Authors:  Kobra Haghighi; George Gardner; Elizabeth Vafiadaki; Mohit Kumar; Lisa C Green; Jianyong Ma; Jeffrey S Crocker; Sheryl Koch; Demetrios A Arvanitis; Phillip Bidwell; Jack Rubinstein; Rutger van de Leur; Pieter A Doevendans; Fadi G Akar; Michael Tranter; Hong-Sheng Wang; Sakthivel Sadayappan; Deeptankar DeMazumder; Despina Sanoudou; Roger J Hajjar; Francesca Stillitano; Evangelia G Kranias
Journal:  J Pers Med       Date:  2021-06-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.